Arvind Bansal, MD
Pulmonary Disease · Lexington, KYNPI 1962523381
Payments from drug & device makers
Across 181 payments — averaging $20.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$545
- Boehringer Ingelheim$325
- Harmony Biosciences LLC$223
- Sanofi$209
- Jazz Pharmaceuticals Inc.$206
- AstraZeneca$177
- plus $2K from 31 others
What the payments were for
- Travel & lodging$351%
- Food & beverage$3,49094%
- Education$2076%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 35 | $545 |
| Boehringer Ingelheim | 18 | $325 |
| Harmony Biosciences LLC | 8 | $223 |
| Sanofi | 8 | $209 |
| Jazz Pharmaceuticals Inc. | 5 | $206 |
| AstraZeneca | 12 | $177 |
| Regeneron Healthcare Solutions, Inc. | 7 | $164 |
| Grifols USA, LLC | 8 | $162 |
| Insmed, Inc. | 7 | $155 |
| Mylan Specialty L.p. | 9 | $151 |
| ZOLL Respicardia, Inc. | 1 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $113 |
| Genentech USA, Inc. | 7 | $113 |
| Axsome Therapeutics, Inc. | 4 | $93 |
| United Therapeutics Corporation | 4 | $91 |
| Viatris Specialty LLC | 4 | $88 |
| Mallinckrodt Hospital Products Inc. | 3 | $76 |
| Merck | 4 | $72 |
| Verona Pharma, Inc. | 3 | $71 |
| Amgen | 3 | $65 |
| Baxter Healthcare | 2 | $50 |
| Gilead | 3 | $47 |
| Actelion Pharmaceuticals US, Inc. | 2 | $43 |
| Resmed Corp | 2 | $39 |
| AbbVie | 2 | $39 |
| Inspire Medical Systems, Inc. | 2 | $38 |
| Pulmonx Corporation | 1 | $35 |
| Veran Medical Technologies, Inc. | 1 | $35 |
| Paratek Pharmaceuticals, Inc. | 2 | $31 |
| Vifor Pharma, Inc. | 1 | $27 |
| CSL Behring | 1 | $26 |
| Inogen, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $19 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $17 |
| Boston Scientific | 1 | $16 |
| Fisher & Paykel Healthcare Inc | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- remede System$125
How this compares
$3,733 in reported general payments places this provider in the 40th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 79 | $65,259 |
| Dupixent PenDupilumab | 12 | $44,904 |
| Spiriva RespimatTiotropium Bromide | 34 | $26,399 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 29 | $20,493 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $13,862 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $9,788 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 22 | $4,578 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 13 | $4,060 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $2,598 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 37 | $995 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 29 | $855 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 14 | $232 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $545 | $88,909120 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $325 | $46,89363 claims |
| AstraZenecaSymbicort | $177 | $2,59815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Lexington
- Girish NairLexington$852K
- Ketan BuchLexington$150K
- Dennis DohertyLexington$103K
- Ashish MaskeyLexington$94K
- John ThompsonLexington$79K
- Said ChaabanLexington$48K
- Mehdi KhosraviLexington$48K
- Parijat SenLexington$26K
- Harish SeethamrajuLexington$26K
- Anthony GerberLexington$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.